PLS Group shares: light-volume bounce leaves shorts in play as lithium slips

PLS Group shares: light-volume bounce leaves shorts in play as lithium slips

June 29, 2026

SYDNEY, June 30, 2026, 05:02 (AEST)

  • PLS Group Limited closed at A$5.08 on Monday, up 0.79%, after trading between A$4.89 and A$5.09.
  • China lithium fell 0.49% on June 29 to 151,750 yuan a tonne and was down 15.22% over the month.
  • PLS short interest was 8.81% as of June 23, down over the week but up 2.30 percentage points over 30 days.

PLS Group Limited ended Monday higher, but the gain was not backed by much trade. Google Finance showed 17.12 million shares changed hands, less than half the 37.95 million average volume, with the stock closing at A$5.08. The ASX was outside normal cash-market hours at publication; normal trading runs from 9:59 a.m. to 4 p.m. Sydney time.

That is the useful part of the tape. PLS rose 0.79% on a day when the S&P/ASX 200 gained 0.68% to 8,823.4, but the stock remains 25% below its A$6.81 52-week high. Using Google Finance’s 3.22 billion shares outstanding, the fall from that high implies roughly A$5.6 billion in equity value has gone since the peak.

Monday read-throughLatestOne-day moveInvestor signal
PLS Group A$5.08+0.79%Gain came on 45% of average volume
S&P/ASX 2008,823.4+0.68%Broad market was firmer
China lithium151,750 yuan/t-0.49%Spot price still slipping
PLS short interest8.81%T+4 dataShorts lower on week, higher on month

The table points to a stock being pulled in two ways. The share price has stopped falling for now, but lithium pricing is still soft and short sellers have not left the register. ASIC says its short-position reports are aggregated data from short sellers and carry reporting limits; ShortInterest.au says the PLS figure is based on ASIC data with a T+4 lag, so it does not show Monday’s full positioning.

Selected related ASX stocksPriceMonday move
PLS Group A$5.08+0.79%
Core Lithium Ltd A$0.24-3.92%
Liontown Resources Ltd A$1.660.00%
BHP Group Ltd A$59.82+1.41%
Lynas Rare Earths Ltd A$18.52-0.11%

The peer screen was mixed. PLS beat Core Lithium and Liontown, but it did not beat BHP. That matters because PLS is being valued as a lithium rebound stock, not as a plain large-cap miner. A thin-volume rise is less convincing when the commodity line is lower on the same day.

The bull case still rests on tonnes and costs. In April, PLS said March-quarter spodumene concentrate output rose 86% to a record 232,436 dry metric tons, above the Visible Alpha consensus estimate of 215,000 tons. Shipments rose to 195,691 tons, unit operating costs fell 11% to A$520 a ton, and the company reaffirmed 2026 production guidance of 820,000 to 870,000 tons.

“In aggregate, what we’re seeing in the sector is deepening and broadening demand and strong tailwinds for lithium operators,” Chief Executive Dale Henderson told Reuters in April. RBC Capital analyst Kaan Peker called the quarter “a clear beat, driven by stronger-than-expected production and a meaningful cost outperformance.” Reuters

The bear case is simpler. PLS is adding capacity into a market where spot lithium has just pulled back 15% in a month. That does not break the expansion case by itself, but it raises the bar for margins and for the Ngungaju restart, which PLS has said it plans to ramp to steady-state production through the September quarter.

PLS also has a bigger capital call ahead. On June 19, the company approved about A$175 million of pre-final-investment-decision spending for the P2000 project at Pilgangoora, with feasibility study outcomes due in the December quarter. P2000 would lift concentrate capacity to about 2.0 million tonnes a year, but the final decision remains tied to study results, funding and market conditions.

“This pre-FID capital expenditure preserves optionality and maintains momentum along the critical path,” Henderson said in the June 19 statement. For equity holders, that makes Tuesday’s first trade less about Monday’s 4-cent rise and more about whether volume returns while lithium keeps testing the rally. PLS

Mateusz Ługowik

Mateusz Ługowik is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Gdańsk, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • Ramsay Health Care's patient transfer trial draws criticism
    June 29, 2026, 4:23 PM EDT. Ramsay Health Care is running a trial to move privately insured patients from Queensland public hospital emergency departments to its private facilities. The Emergency Department Nurse Liaison program is supposed to ease public ED pressure. Critics say it could mean 'cherrypicking' low-cost, high-turnover cases for private hospitals. Health Consumers Queensland says some patients might feel pushed toward private care. Over 2,000 patients have been moved so far. Some want the program fully reviewed before it goes national. Ramsay posted a half-year net profit of AUD 160.7 million.